ReBalance (sulfadiazine and pyrimethamine) Antiprotozoal Oral Suspension for Horses

Prior to treatment with ReBalance Antiprotozoal Oral Suspension， EPM should be distinguished from the diseases that may cause ataxia in horses. Injuries or lameness may also complicate the evaluation of an animal with EPM. In most instances， ataxia due to EPM is asymmetrical and affects the front and/or the hind limbs.

Treatment may cause generalized bone marrow suppression， anemia， leukopenia， neutropenia and thrombocytopenia. A complete blood count (CBC) should be performed monthly to monitor horses for development of these conditions. The administration of the drug may need to be discontinued and/or treatments for bone marrow suppression initiated.

Worsened neurologic deficits (treatment crisis) may be observed during a period beginning with the first few days of treatment with ReBalance Antiprotozoal Oral Suspension and ranging out to 5 weeks. This neurologic deficit exacerbation may be the result of an inflammatory reaction to the dying parasites in the CNS tissue.

The safe use of ReBalance Antiprotozoal Oral Suspension in horses used for breeding purposes during pregnancy， or in lactating mares has not been evaluated. The safety of ReBalance Antiprotozoal Oral Suspension with concomitant therapies in horses has not been evaluated.